{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025781","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-08-05T11:00:10+00:00","discovered_at":"2026-08-05T11:05:00.318095+00:00","generated_at":"2026-08-05T11:05:11.813635+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eton licenses late-stage ASN-001 (timolol gel) for infantile hemangiomas; $3M upfront","bullets":["Upfront license fee $3M to Auson; milestones up to $33.5M based on sales thresholds; tiered royalties 10-15%.","Phase II/III trial: 56% (BID) and 42% (TID) elimination/near-elimination at week 24 vs 15% placebo.","NDA submission planned for 2H 2027; potential approval and launch in 2028.","Estimated 20,000-30,000 patients annually; complementary to HEMANGEOL, leveraging existing commercial infrastructure.","Patent protection through 2044; additional patent application pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025781","json":"https://secwatch.observer/filing/0001437749-26-025781.json","markdown":"https://secwatch.observer/filing/0001437749-26-025781.md","text":"https://secwatch.observer/filing/0001437749-26-025781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/0001437749-26-025781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/eton20260803_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:05:11.813635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}